Shopping Cart
Remove All
Your shopping cart is currently empty
Adebrelimab
(Synonyms: SHR-1316, SHR1316, HTI-1316, HTI1316, HTI-1088, HTI1088) Copy Product Info
🥰Excellent
Synonyms: SHR-1316, SHR1316, HTI-1316, HTI1316, HTI-1088, HTI1088
Catalog No. T76899 Copy Product Info
🥰Excellent
Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting PD-L1 with antitumor activity for the study of solid tumors.
Adebrelimab
Cas No. 2247114-85-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | In Stock | In Stock | |
| 5 mg | $645 | In Stock | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,530 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock | |
| 100 mg | $2,790 | 7-10 days | 7-10 days |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.8% (SDS-PAGE); 97.5% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting PD-L1 with antitumor activity for the study of solid tumors. |
| In vitro | Adebrelimab (0.06-1 mg/mL; treated for 48 hours) significantly inhibited the proliferation, migration, and invasion of SK-BR-3 and AU565 cells. [1] Adebrelimab (0.1-1 mg/mL; 48 hrs) decreased the expression of PD-L1, p-PI3K, and p-AKT, and increased the expression of FOXO1. [1] |
| In vivo | Adebrelimab (200 μg; administered 3 times per week for 21 days) showed significant inhibition of tumor growth. [1] |
| Synonyms | SHR-1316, SHR1316, HTI-1316, HTI1316, HTI-1088, HTI1088 |
| Reactivity | Human |
| Verified Activity | Immobilized Human PD-L1 Protein (His) (TMPY-04343) at 1 μg/mL (100 μL/well) can bind Adebrelimab. The EC50 is 10.54 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | B7-H1/PD-L1/CD274 |
| Molecular Weight | 145.54 kDa |
| Cas No. | 2247114-85-6 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Adebrelimab in vivo | Adebrelimab in vitro | Adebrelimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.